Switching to Tirzepatide Outweighs Upping Dulaglutide Dose

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...

GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!

Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.

We share that with you as Cash Back. Everyone wins!  SIGN UP FOR FREE!

Get In Touch

COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774

(916) 619-1308

teosmoot@gmail.com

Follow Us
Flickr Photos

Copyright © 2024 Cool Room Entertainment. All Rights Reserved